ArticleBMC pharmacology & toxicology2025
Instantaneous carboxyhemoglobin level change due to smoking and analysis of baseline SpCO in smokers.
Article in BMC pharmacology & toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of this study was to investigate baseline carboxyhemoglobin saturation (SpCO) values in smokers and to show the relationship between SpCO and age, years smoking, cigarettes per day, and nicotine dependence. We also analyzed the changes in carboxyhemoglobin in the body during active smoking.
methodsThis prospective cohort study involved 136 outdoor smokers and 60 controls who had never smoked. SpCO, heart rate (HR), and oxyhemoglobin saturation (SpO2) values were recorded with a CO-oximeter device before, during, and two minutes after smoking. Changes during active smoking were analyzed, and all parameters were compared between smoking and non-smoking groups. Age, BMI, years smoking, cigarettes per day, and Fagerström nicotine dependence (FTND) level were correlated with baseline SpCO.
resultsThe mean age of smokers was 32.3 years (70.6% male; 22.79% with comorbidities), while the mean age of non-smokers was 36.7 years (38.3% male). The SpCO and HR were significantly higher during (p = 0.006, p < 0.001) and after (p = 0.015, p < 0.001) smoking than the pre-cigarette levels. There was a significant difference between smokers (3.07) and non-smokers (1.77) in terms of baseline SpCO (p < 0.001). Correlation analysis showed that age, years smoking, and nicotine dependence were positively correlated with baseline SpCO. In the ROC analysis, the AUC value for SpCO was 0.705 and the optimal cut-off value was 1.50. In addition, 83% of smokers had a baseline SpCO value below 5%.
conclusionIn this study, the baseline SpCO values of smokers were found to be approximately 200% higher than those of non-smokers. In addition, SpCO and HR increased during active smoking. However, 83% of smokers had a baseline SpCO below 5% and just 2 (1.47%) smokers had a baseline SpCO value above 9%, suggesting that the intoxication level of 9% in smokers should be reconsidered. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.